1. Home
  2. CHMI vs CRDF Comparison

CHMI vs CRDF Comparison

Compare CHMI & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cherry Hill Mortgage Investment Corporation

CHMI

Cherry Hill Mortgage Investment Corporation

HOLD

Current Price

$2.53

Market Cap

108.3M

Sector

Real Estate

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$0.90

Market Cap

82.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHMI
CRDF
Founded
2012
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
108.3M
82.5M
IPO Year
2013
2012

Fundamental Metrics

Financial Performance
Metric
CHMI
CRDF
Price
$2.53
$0.90
Analyst Decision
Hold
Buy
Analyst Count
2
6
Target Price
$3.10
★ $5.81
AVG Volume (30 Days)
172.5K
★ 418.7K
Earning Date
11-05-2026
11-05-2026
Dividend Yield
★ 15.75%
N/A
EPS Growth
N/A
★ 27.37
EPS
★ N/A
N/A
Revenue
N/A
★ $365,993.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.70
$8.70
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 49.61
52 Week Low
$2.17
$0.76
52 Week High
$2.98
$3.31

Technical Indicators

Market Signals
Indicator
CHMI
CRDF
Relative Strength Index (RSI) 41.76 33.79
Support Level $2.30 $0.88
Resistance Level $2.73 $1.13
Average True Range (ATR) 0.06 0.06
MACD 0.00 -0.02
Stochastic Oscillator 47.22 10.34

Price Performance

Historical Comparison
CHMI
CRDF

About CHMI Cherry Hill Mortgage Investment Corporation

Cherry Hill Mortgage Investment Corp is a fully integrated, internally managed residential real estate finance company focused on acquiring, investing in and managing residential mortgage assets in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.

Share on Social Networks: